Current Trends in Clinical Trials for Merkel Cell Carcinoma (MCC)
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with high rates of recurrence and metastasis.
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with high rates of recurrence and metastasis. The treatment of MCC has historically involved surgery, radiation, and chemotherapy; however, current clinical trials are investigating immunotherapies, intratumoral injections, and combination therapies to improve outcomes. This review explores the current trends in clinical trials for MCC, highlighting recent advances in management.
The paper reviews emerging therapies—particularly immunotherapies and combination strategies—in melanoma‑related skin cancers, aiming to improve survival and reduce recurrence.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy
- Repurposed pinworm medication shows ‘promise’ as treatment for Merkel cell carcinoma
- Merkel Cell Carcinoma: Epidemiology, Target, and Therapy
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
- Avelumab in patients with chemotherapy‑refractory metastatic Merkel cell carcinoma: a multicentre, single‑group, open‑label, phase 2 trial